Preparation method and application of anti-atherosclerosis hybrid exosome

By using M2 macrophage exosomes and liposome hybrid vectors, loading Ferrostatin-1 and atorvastatin, the problem of insufficient stability and targeting of drugs in the prior art in the treatment of atherosclerosis is solved. , multi-angle treatment of atherosclerosis has been achieved, significantly improving the treatment effect.

CN118975985AActive Publication Date: 2024-11-19SHANDONG UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410991209.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-19
Estimated Expiration
2044-07-23

AI Technical Summary

Technical Problem

Current statins are poor in the treatment of atherosclerosis due to the limited liver first pass effect and circulatory clearance, and lack of targeted drugs to target iron death.

Method used

The hybrid composed of M2 macrophage exosomes and liposomes is used as a carrier, and Ferrostatin-1 and atorvastatin are loaded to avoid the first pass effect of the liver through intravenous injection, achieving multi-angle treatment for atherosclerosis.

Benefits of technology

This method improves the stability and targeting ability of the drug, effectively delivers it to the atherosclerotic plaque area, inhibits ferrous death, reduces inflammation, promotes cholesterol excretion and apoptotic cell phagocytosis, and significantly improves the therapeutic effect of atherosclerosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118975985A_ABST
    Figure CN118975985A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical preparations and biological medicines, and relates to an anti-atherosclerosis hybrid exosome as well as a preparation method and application thereof. A hybrid composed of an M2 macrophage exosome and a liposome is used as a carrier, and the carrier is loaded with a ferroptosis inhibitor and atorvastatin; the drug loading capacity of the ferroptosis inhibitor is 1.55 to 2.57 percent, and the encapsulation efficiency of the ferroptosis inhibitor is 11.99 to 49.86 percent; the drug loading capacity of the atorvastatin is 1.48 to 12.66 percent, and the encapsulation efficiency of the atorvastatin is 46.4 to 77.31 percent. The hybrid exosome provided by the invention has inflammation targeting ability and higher stability, and can avoid the first pass effect of the liver and the clearing effect of the circulatory system through intravenous injection; meanwhile, the hybrid exosome has the effects of inhibiting ferroptosis, promoting cholesterol outflow, promoting cell burial, resisting inflammation, regulating immune microenvironment and the like, and can be used for performing multi-angle treatment on the atherosclerosis, so that the hybrid exosome has a better atherosclerosis treatment effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical preparations and biomedicine, and relates to a preparation method and application of anti-atherosclerotic hybrid exosomes. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Statins have been a commonly used drug for the clinical treatment of atherosclerosis and are currently mainly administered orally. However, the first-pass effect from the liver and the clearance from the circulatory system greatly limit the therapeutic effect of the drug. In addition, ferroptosis is one of the pathogenic factors of atherosclerosis, and there are currently few targeted drugs, which also limits the multi-angle treatment of atherosclerosis. Summary of the invention

[0004] In order to address the deficiencies of the prior art, the purpose of the present invention is to provide a preparation method and application of anti-atherosclerosis hybrid exosomes. The anti-atherosclerosis hybrid exosomes provided by the present invention have inflammation targeting ability and higher stability, and can avoid the first-pass effect of the liver and the clearance of the circulatory system through intravenous injection; at the same time, the anti-atherosclerosis hybrid exosomes provided by the present invention can treat atherosclerosis from multiple angles, thereby having a better therapeutic effect on atherosclerosis.

[0005] In order to achieve the above object, the technical solution of the present invention is:

[0006] On the one hand, an anti-atherosclerosis hybrid exosome uses a hybrid composed of M2 macrophage exosomes and liposomes as a carrier, and the carrier is loaded with Ferrostatin-1 and atorvastatin; the drug loading amount and encapsulation efficiency of Ferrostatin-1 are 1.55-2.57% and 11.99-49.86%, respectively; the drug loading amount and encapsulation efficiency of atorvastatin are 1.48-12.66% and 46.4-77.31%, respectively.

[0007] Ferrostatin-1 is a ferroptosis inhibitor. The main reason why it is not currently used to treat atherosclerosis is that Ferrostatin-1 is metabolized quickly in the body and is difficult to reach the atherosclerotic (AS) plaque area, so it cannot play its role. The present invention uses liposomes to load Ferrostatin-1 and atorvastatin, in order to achieve multi-angle treatment of atherosclerosis including inhibition of ferroptosis. However, studies have found that only using liposomes to load Ferrostatin-1 and atorvastatin has poor stability and cannot aggregate in the AS plaque area, making it difficult to achieve the treatment of atherosclerosis.

[0008] To this end, the present invention uses a hybrid composed of M2 macrophage exosomes and liposomes as a carrier, which not only has the ability to target inflammation and higher stability, and can efficiently deliver Ferrostatin-1 and atorvastatin to the AS plaque area, but also has the general ability of macrophages to exert an anti-inflammatory effect. In addition, the carried protein can promote the M2 polarization of macrophages and regulate the immune microenvironment; after atorvastatin is taken up, it effectively regulates the cholesterol efflux of endothelial cells and macrophages at the plaque, and can also exert a certain degree of anti-inflammatory effect, reducing the production of ROS in target cells. In addition, it can effectively promote the phagocytosis of apoptotic cells at the plaque by macrophages and reduce the accumulation of apoptotic cells; Ferrostatin-1 can effectively inhibit the ferroptosis of target cells, reduce the production of lipid peroxides, and reduce the consumption of glutathione (GSH), and can also promote the phagocytosis of macrophages. The action of multiple factors makes this nano-platform have a better therapeutic effect on atherosclerosis.

[0009] In addition, the present invention also shows that the hybrid composed of M2 macrophage exosomes and liposomes as a carrier has a high drug loading capacity and encapsulation rate for Ferrostatin-1 and atorvastatin, thereby enabling the obtained anti-atherosclerosis hybrid exosomes to achieve the above-mentioned therapeutic effect on atherosclerosis.

[0010] On the other hand, a method for preparing the above-mentioned anti-atherosclerosis hybrid exosomes comprises the following steps:

[0011] DPPC (dipalmitoylphosphatidylcholine), Ferrostatin-1, and atorvastatin were mixed to form a film;

[0012] Obtain M2 macrophage exosomes from M2 polarized cells;

[0013] The M2 macrophage exosomes are resuspended, mixed with the film, and extruded using a liposome extruder to obtain the product.

[0014] In a third aspect, a pharmaceutical composition comprises the above-mentioned anti-atherosclerotic hybrid exosomes and pharmaceutical excipients.

[0015] In a fourth aspect, a use of the anti-atherosclerotic hybrid exosomes or pharmaceutical composition described above in the preparation of an anti-atherosclerotic product.

[0016] The beneficial effects of the present invention are:

[0017] 1. The anti-atherosclerosis hybrid exosomes provided by the present invention contain atorvastatin and Ferrostatin-1, which are used for anti-inflammatory treatment of atherosclerosis, can promote cholesterol excretion, reduce ROS, inhibit ferroptosis, promote cell death and remodeling of the immune microenvironment.

[0018] 2. The anti-atherosclerosis hybrid exosomes provided by the present invention use a hybrid constructed by M2 macrophage exosomes and liposomes as a carrier, which can achieve targeted effects on inflammatory sites with the help of chemotactic proteins on the surface of exosomes; at the same time, through the proteins and cytokines carried by the exosomes, the anti-inflammatory M2 phenotype polarization of macrophages in the microenvironment is achieved, thereby reshaping the microenvironment.

[0019] 3. The anti-atherosclerosis hybrid exosomes provided by the present invention can promote the phagocytosis and clearance of apoptotic cells by macrophages, thereby alleviating the accumulation of apoptotic cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0021] Figure 1 Schematic diagram of the synthesis of EL@TF in an embodiment of the present invention.

[0022] Figure 2 Schematic diagram of the particle size distribution of exosomes (replaced by E), L@TF, and EL@TF in the embodiments of the present invention.

[0023] Figure 3 These are transmission electron microscopy images of (A) EL@TF, (B) L@TF, and (C) exosomes in the embodiments of the present invention.

[0024] Figure 4 : is the fluorescence spectrum of E, L, and EL in the embodiment of the present invention.

[0025] Figure 5 It is the fluorescence confocal image of E, L, and EL in the embodiment of the present invention.

[0026] Figure 6 This is a diagram showing the hemolytic test results of EL@TF in an embodiment of the present invention.

[0027] Figure 7 1 is the particle size variation curve of L@TF and EL@TF in the embodiment of the present invention.

[0028] Figure 8 The figures are the results of the cytotoxicity experiments of L@TF and EL@TF in the examples of the present invention; the cell line in Figure A is HUVECs cells, and the cell line in Figure B is RAW264.7 cells.

[0029] Fig. 9 The graphs are the results of L@TF and EL@TF uptake by RAW264.7 cells under different treatments in the examples of the present invention; Figure A is a fluorescence confocal image, and Figure B is a flow cytometry quantitative result.

[0030] Fig.10 These are the results of the targeting study of L@TF and EL@TF in the embodiments of the present invention; Figure A is a fluorescence confocal image, and Figure B is a flow cytometry quantitative result.

[0031] Fig.11 These are the results of the in vivo targeting study of L@TF and EL@TF in the embodiments of the present invention; Figure A is the fluorescence image of EL in the aorta, Figure B is the fluorescence image of L in the aorta, and Figure C is the fluorescence quantification result. DETAILED DESCRIPTION

[0032] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0033] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0034] In view of the poor therapeutic effect of existing drugs on atherosclerosis, the present invention proposes an anti-atherosclerosis hybrid exosome and a preparation method and application thereof.

[0035] A typical embodiment of the present invention provides an anti-atherosclerosis hybrid exosome, using a hybrid composed of M2 macrophage exosomes and liposomes as a carrier, and the carrier is loaded with Ferrostatin-1 and atorvastatin; the drug loading amount and encapsulation efficiency of Ferrostatin-1 are 1.55-2.57% and 11.99-49.86%, respectively; the drug loading amount and encapsulation efficiency of atorvastatin are 1.48-12.66% and 46.4-77.31%, respectively.

[0036] Another embodiment of the present invention provides a method for preparing the above-mentioned anti-atherosclerosis hybrid exosomes, comprising the following steps:

[0037] DPPC, Ferrostatin-1, and atorvastatin were mixed to form a film;

[0038] Obtain M2 macrophage exosomes from M2 polarized cells;

[0039] The M2 macrophage exosomes are resuspended, mixed with the film, and extruded using a liposome extruder to obtain the product.

[0040] In some embodiments, DPPC (dipalmitoylphosphatidylcholine), Ferrostatin-1, and atorvastatin are added to an organic solvent to dissolve, and then the organic solvent is evaporated to remove to obtain a film. Specifically, the organic solvent is methanol and / or dichloromethane, preferably a mixture of methanol and dichloromethane. The volume ratio of methanol to dichloromethane is 1:1.5 to 2.5. Specifically, the temperature at which the organic solvent evaporates is 40 to 45°C.

[0041] In some embodiments, the mass ratio of the total mass of atorvastatin and Ferrostatin-1 to DPPC is 2:5-30.

[0042] In some embodiments, the mass ratio of atorvastatin to Ferrostatin-1 is 1:0.5-2.

[0043] In some embodiments, RAW264.7 cells are treated with IL-4 to obtain M2 polarized cells. Specifically, the concentration of IL-4 is 15 to 25 ng / ml, and the treatment time is 24 to 48 hours.

[0044] In some embodiments, the process of obtaining M2 macrophage exosomes from M2 polarized cells is: collecting the cell culture fluid of M2 polarized cells, removing cells, dead cells and cell debris, and then ultracentrifuging to obtain exosomes and protein precipitates, and then resuspending the precipitate with PBS, and ultracentrifuging to finally obtain exosome precipitates. Specifically, the centrifugation conditions for removing cells are 250-350g centrifugation for 5-15min; the centrifugation conditions for removing dead cells are 1900-2100g centrifugation for 5-15min; the centrifugation conditions for removing cell debris are 9000-11000g centrifugation for 25-35min. Specifically, the centrifugation conditions for ultracentrifugation to obtain exosomes are 119000-121000g centrifugation for 65-75min. Specifically, the centrifugation conditions for ultracentrifugation to obtain exosome precipitates are 119000-121000g centrifugation for 65-75min.

[0045] In some embodiments, the resuspended M2 macrophage exosomes are added to a container containing a film, ultrasonically hydrated at 40-45°C, ultrasonically dispersed in an ice-water bath, centrifuged to remove free drugs, and then extruded using a liposome extruder. Specifically, the ultrasonic hydration time is 15-25 minutes. Specifically, the ultrasonic dispersion in the ice-water bath is 4-6 minutes. Specifically, the air of the ultrasonic dispersion in the ice-water bath is 35-45W. Specifically, the conditions for centrifugal removal of free drugs are: 2500-3500rpm, 5-15min.

[0046] In some embodiments, during the extrusion process using a liposome extruder, physical extrusion is performed through a 190-210 nm and a 90-100 nm porous membrane in sequence for several cycles. Specifically, the porous membrane is made of polycarbonate. Specifically, the number of cycles for the 190-210 nm porous membrane is 8-10; the number of cycles for the 90-100 nm porous membrane is 4-6.

[0047] A third embodiment of the present invention provides a pharmaceutical composition comprising the above-mentioned anti-atherosclerosis hybrid exosomes and pharmaceutical excipients.

[0048] In some embodiments, the pharmaceutical composition is administered by intravenous injection.

[0049] In some embodiments, the pharmaceutical excipients are water, buffer solution, preservatives, solubilizers, etc.

[0050] A fourth embodiment of the present invention provides a use of the above-mentioned anti-atherosclerotic hybrid exosomes or pharmaceutical composition in the preparation of an anti-atherosclerotic product.

[0051] Specifically, the product is a medicine.

[0052] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0053] Experimental materials: dipalmitoylphosphatidylcholine (DPPC, Anergy), Ferrostatin-1 (Shanghai Bidex), atorvastatin (Roen), dichloromethane (Tianjin Fuyu), methanol (Tianjin Fuyu).

[0054] Embodiment 1:

[0055] 12 mg DPPC, 0.8 mg Ferrostatin-1, and 1.6 mg atorvastatin were added to a round-bottom flask, and 2 ml of a mixed solvent of dichloromethane and methanol (dichloromethane to methanol ratio of 2:1) was added to dissolve, and the organic solvent was removed by rotary evaporation at 40 degrees Celsius for 30 minutes to form a thin film. RAW264.7 cells were treated with IL-4 (20 ng / ml) for 48 hours to obtain M2 polarized cells. The cell culture medium was collected, centrifuged at 300g for 10 minutes to remove cells, 2000g for 10 minutes to remove dead cells, and 10000g for 30 minutes to remove cell debris, etc. The supernatant was filtered through a 0.22 μm filter membrane, and centrifuged at 120000g for 70 minutes to obtain exosomes and protein precipitates, then the precipitate was resuspended in PBS and centrifuged at 120000g for 70 minutes to finally obtain the exosome precipitate. After 0.24 mg protein equivalent exosomes were resuspended in 5 ml PBS, added to the round-bottom flask formed with the film, hydrated by ultrasonication in a water bath at 42 degrees Celsius for 20 min, ultrasonically dispersed in an ice water bath for 5 min with a 40W probe, centrifuged at 3000 rpm for 10 min to remove free drugs, and physically extruded through 200 nm and 100 nm polycarbonate porous membranes in a microliposome extruder for 9 and 5 cycles, respectively, to obtain EL@TF (synthesis schematic diagram can be seen Figure 1 ), in which the drug loading of Fer-1 and atorvastatin were 2.05±0.15% and 7.10±0.29%, and the encapsulation efficiency were 35.78±3.32% and 73.45±2.58%, respectively.

[0056] Embodiment 2:

[0057] 12mg DPPC, 0.8mg Ferrostatin-1, and 1.6mg atorvastatin were added to a round-bottom flask, and 2ml of a mixed solvent of dichloromethane and methanol (dichloromethane and methanol ratio is 2:1) was added to dissolve, and the organic solvent was removed by rotary evaporation at 40 degrees Celsius for 30 minutes to form a thin film. After resuspending with 5ml PBS, it was added to the round-bottom flask with the thin film formed, hydrated by ultrasonication in a water bath at 42 degrees Celsius for 20 minutes, ultrasonically dispersed in an ice water bath with a 40w probe for 5 minutes, centrifuged at 3000rpm for 10 minutes to remove free drugs, and physically extruded through 200nm and 100nm polycarbonate porous membranes in a micro-liposome extruder for 9 and 5 cycles respectively to obtain L@TF.

[0058] Embodiment 3:

[0059] The particle sizes of the EL@TF obtained in Example 1 and the L@TF obtained in Example 2 were measured. Figure 2 As shown, the particle size increased by about 29 nm compared with L@TF and EL@TF, indicating the successful incorporation of exosomes. Figure 3 Transmission electron microscopy more intuitively proved that the exosomes were successfully incorporated into the liposome membrane to form uniform EL@TF bionic nanoparticles (hybrid exosomes).

[0060] Embodiment 4:

[0061] Take 12mg DPPC and 0.12mg DiO and add 2ml of a mixed solvent of dichloromethane and methanol (the ratio of dichloromethane to methanol is 2:1) to dissolve, and remove the organic solvent by rotary evaporation at 40 degrees Celsius for 30 minutes to form a thin film. Follow the steps shown in Example 1 to complete the operation to obtain DiO-labeled L. Add 2.4μg of dye Dil to the PBS solution of exosomes equivalent to 0.24mg protein, and remove the free dye by ultrafiltration to obtain Dil-labeled E. For EL, add the PBS solution of Dil-labeled exosomes to a round-bottom flask, and follow the steps shown in Example 1 to obtain fluorescently labeled EL. The obtained fluorescently labeled E, L, and EL solutions were scanned at an excitation wavelength of 450nm to obtain the fluorescence emission spectra in the wavelength range of 470-650nm, as shown in Figure 4 As shown, the fluorescence emission peak of EL at 560 nm proves the successful fusion of EL. Figure 5 The confocal fluorescence images also demonstrated the successful integration of EL.

[0062] Embodiment 5:

[0063] Add 3 ml of rat blood to a 5 ml centrifuge tube and centrifuge at 3000 rpm for 10 min. After centrifugation, discard the supernatant, add 3 ml of saline to the precipitate, and pipette 5 to 6 times to resuspend the precipitate, and centrifuge at 3000 rpm for 10 min. Repeat the above operation 3 to 4 times. When the supernatant is colorless, the resulting precipitate is the packed red blood cells. Use a pipette to draw 1 ml of packed red blood cells into a 50 ml volumetric flask, add saline to dilute and make up to volume to obtain a 2% red blood cell suspension. Prepare a blank hybrid exosome solution with a concentration of 5 mg / ml, add the corresponding volume of reagent to each centrifuge tube, and obtain blank hybrid exosome solutions with final concentrations of 0.1, 0.25, 0.5, 0.75, and 1 mg / ml, respectively. All centrifuge tubes were incubated in a 37°C water bath for 1 hour, centrifuged at 3000 rpm for 10 minutes, the supernatant was aspirated with a pipette, and the absorbance of each group was measured at a wavelength of 541 nm using an ultraviolet spectrophotometer to calculate the hemolysis rate. Figure 6 As shown in the figure, the hemolysis rate of EL@TF at the set concentration was less than 5%, which showed good blood compatibility.

[0064] Embodiment 6:

[0065] L@TF and EL@TF were placed in PBS (pH 7.4) containing 10% plasma and stored at 4°C. The particle size of the preparations in each experimental group was measured on days 0, 1, 3, 5, and 7. Figure 7 As shown, the particle size of the preparation did not change much within seven days, indicating that the preparation had good stability.

[0066] Example 7: RAW264.7 and HUVECs cells were inoculated in 96-well plates and cultured overnight, and then the cells were co-cultured with different concentrations of preparations for 24 hours. After washing with PBS, 100 μl of 10% CCK-8 solution was added to each well and incubated at 37°C for 2 hours. The absorbance at a wavelength of 450 nm was recorded using an ELISA reader. The results are shown in Figure 7. Figure 8 As shown, the cell survival rate was above 80%, and the safety was good.

[0067] Embodiment 8:

[0068] RAW264.7 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS), penicillin (100 U / mL) and streptomycin (100 μg / mL). All cells were kept at 37°C and 5% CO. 2 Cultivated in an atmosphere of

[0069] The steps for preparing L@TF and EL@TF loaded with C6 were as shown in Example 1, except that the drug was replaced by C6.

[0070] RAW264.7 cells were cultured at 2 × 10 5 The cells were seeded at a density of 10 cells / well in a 12-well culture plate and induced with PBS, 1μg / ml lps, 1μg / ml lps + 20μg / ml ox-LDL for 24h. The cells were then treated with L@C6 solution or EL@C6 for 4h. The cells were collected and washed with PBS and analyzed by flow cytometry. Fig. 9 As shown, obvious uptake fluorescence of L@C6 can be detected in macrophages in three different states, indicating that L@C6 does not have the function of long circulation and immune escape in vivo, and the uptake of EL@C6 by uninduced macrophages is lower than that of L@C6, which may be due to the CD47 protein expressed on the surface of EL. In addition, since the CCR2 protein on the surface of EL can bind to the MCP-1 secreted by inflammatory macrophages and foam cells, the induced macrophages can effectively take up EL@C6, which is beneficial to the accumulation of the preparation.

[0071] Embodiment 9:

[0072] HUVECs cells were used as the test cell line. HUVECs cells were cultured in DMEM / F12 medium containing 10% fetal bovine serum (FBS), penicillin (100 U / mL) and streptomycin (100 μg / mL). All cells were kept at 37°C and 5% CO 2 Cultivated in an atmosphere of

[0073] HUVECs cells were cultured at 10 5 The cells were seeded at a density of 10 cells / well in a 12-well culture plate and induced with PBS and 1 μg / mL llps for 24 h. The cells were then treated with L@C6 solution or EL@C6 for 1 h and 4 h, respectively. The cells were collected and washed with PBS and analyzed by flow cytometry. The results are shown in Fig.10 As shown, the uptake of EL@C6 by activated inflammatory endothelial cells increased, which was due to the expression of integrin β-1, LFA1, CD44, and CCR2 on the membrane of M2 exosomes, and their binding to VCAM-1, ICAM-1, and E-selectin on inflammatory endothelial cells, and to MCP-1 at the inflammatory site, demonstrating the targeting effect on the inflammatory site.

[0074] Embodiment 10:

[0075] ApoE- / - atherosclerotic mice were used as experimental animals. Liposomes and hybrid exosomes encapsulating DiD fluorescent dye were prepared according to the method shown in Example 4. Mice with atherosclerosis were randomly divided into two groups, three mice in each group, and DiD-L and DiD-EL were injected into the tail vein respectively.

[0076] Ten hours after the injection, the mice were anesthetized by intraperitoneal injection of ready-to-use 1.25% Avertin anesthetic, and the mice were perfused with PBS. After the outflowing fluid became clear, it was replaced with 4% paraformaldehyde and continued to be perfused. After the tail of the mouse was lifted up, the aorta, heart, liver, spleen, lung and kidney of the mouse were separated, and the aorta of the mouse was imaged and fluorescence quantified using a small animal in vivo imaging system. Fig.11 As shown, the accumulation of Did-EL in the aortic lesion site was significantly greater than that of Did-L (p<0.01), indicating that EL has good plaque targeting in vivo, which is due to the inflammatory tropism conferred by the inflammatory chemotactic protein on the surface of EL.

[0077] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of them with equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. An anti-atherosclerotic hybrid exosome, characterized in that: A hybrid composed of M2 macrophage exosomes and liposomes is used as a carrier, and the carrier is loaded with Ferrostatin-1 and atorvastatin; The drug loading and encapsulation efficiency of ferrostatin-1 were 1.55-2.57% and 11.99-49.86% respectively; the drug loading and encapsulation efficiency of atorvastatin were 1.48-12.66% and 46.4-77.31% respectively.

2. A method for preparing the anti-atherosclerotic hybrid exosomes according to claim 1, characterized in that: The steps include: DPPC, Ferrostatin-1, and atorvastatin were mixed to form a film; Obtain M2 macrophage exosomes from M2 polarized cells; The M2 macrophage exosomes are resuspended, mixed with the film, and extruded using a liposome extruder to obtain the product.

3. The method for preparing anti-atherosclerotic hybrid exosomes according to claim 2, characterized in that: DPPC, Ferrostatin-1 and atorvastatin are added to an organic solvent to dissolve, and then the organic solvent is evaporated to obtain a film; alternatively, the organic solvent is methanol and / or dichloromethane; alternatively, the volume ratio of methanol to dichloromethane is 1:1.5-2.5; alternatively, the temperature at which the organic solvent is evaporated is 40-45°C.

4. The method for preparing anti-atherosclerotic hybrid exosomes according to claim 2, characterized in that: The mass ratio of the total mass of atorvastatin and Ferrostatin-1 to DPPC is 2:5-30; Alternatively, the mass ratio of atorvastatin to Ferrostatin-1 is 1:0.5-2.

5. The method for preparing anti-atherosclerotic hybrid exosomes according to claim 2, characterized in that: RAW264.7 cells were treated with IL-4 to obtain M2 polarized cells; alternatively, the concentration of IL-4 was 15-25 ng / ml; and the treatment time was 24-48 h.

6. The method for preparing anti-atherosclerotic hybrid exosomes according to claim 2, characterized in that: The process of obtaining M2 macrophage exosomes from M2 polarized cells is as follows: collecting the cell culture fluid of M2 polarized cells, removing cells, dead cells and cell debris, and then ultracentrifuging to obtain exosomes and protein precipitates, then resuspending the precipitates with PBS, and ultracentrifuging to finally obtain exosome precipitates; alternatively, the centrifugation conditions for removing cells are 250-350g centrifugation for 5-15 minutes; the centrifugation conditions for removing dead cells are 1900-2100g centrifugation for 5-15 minutes; the centrifugation conditions for removing cell debris are 9000-11000g centrifugation for 25-35 minutes; alternatively, the centrifugation conditions for ultracentrifugation to obtain exosomes are 119000-121000g centrifugation for 65-75 minutes; alternatively, the centrifugation conditions for ultracentrifugation to obtain exosome precipitates are 119000-121000g centrifugation for 65-75 minutes.

7. The method for preparing anti-atherosclerotic hybrid exosomes according to claim 2, characterized in that: The resuspended M2 macrophage exosomes are added to a container containing a film, ultrasonically hydrated at 40-45°C, ultrasonically dispersed in an ice water bath, centrifuged to remove free drugs, and then extruded using a liposome extruder; alternatively, the ultrasonic hydration time is 15-25 minutes; alternatively, the ultrasonic dispersion in an ice water bath is 4-6 minutes; alternatively, the ultrasonic dispersion in an ice water bath is 35-45W; alternatively, the conditions for centrifugal removal of free drugs are: 2500-3500rpm, 5-15 minutes; Alternatively, during extrusion using a liposome extruder, physical extrusion is performed through 190-210 nm and 90-100 nm porous membranes in sequence for several cycles; alternatively, the porous membrane is made of polycarbonate; alternatively, the number of cycles for the 190-210 nm porous membrane is 8-10; and the number of cycles for the 90-100 nm porous membrane is 4-6.

8. A pharmaceutical composition, characterized in that: It comprises the anti-atherosclerotic hybrid exosomes according to claim 1 and pharmaceutical excipients.

9. The pharmaceutical composition according to claim 8, characterized in that: The pharmaceutical composition is administered by intravenous injection; Or, the pharmaceutical excipient is water, a buffer solution, a preservative or a solubilizer.

10. Use of the anti-atherosclerotic hybrid exosomes according to claim 1 or the pharmaceutical composition according to claim 8 or 9 in the preparation of an anti-atherosclerotic product.

Citation Information

Patent Citations

  • Macrophage-derived exosome preparation for resisting inflammation and promoting tissue regeneration and preparation method and application of macrophage-derived exosome preparation

    CN113797229A

  • Application of M2 type macrophage exosome in preparation of medicine for treating myocardial ischemia-reperfusion injury

    CN115998768A

  • Application of anhydroicaritin in preparation of medicine for inhibiting macrophage ferroptosis to treat atherosclerosis

    CN116407531A

  • Nanocomposite carrier as well as preparation method and application thereof

    CN117731631A

  • Targeted atherosclerosis liposome nano-carrier delivery system and preparation method thereof

    CN117750943A